- Home
- TALO vs KOD Comparison
TALO vs KOD Comparison
Compare TALO & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | KOD |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | 121 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TALO | KOD |
|---|---|---|
| Price | $13.79 | $23.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $54.88 | $28.29 |
| AVG Volume (30 Days) | ★ 2.2M | 503.1K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.60 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,780,070,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.23 | $1.92 |
| 52 Week High | $13.85 | $31.18 |
Technical Indicators
Market Signals| Indicator | TALO | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 41.55 |
| Support Level | $10.49 | $21.19 |
| Resistance Level | $13.85 | $29.17 |
| Average True Range (ATR) | 0.63 | 1.70 |
| MACD | 0.05 | -0.35 |
| Stochastic Oscillator | 97.02 | 8.59 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.